GBG HOME

Deutscher Krebskongress

10.11.2022

DKK

Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress  vom 13. – 16. November 2022 in Berlin vertreten.

GeparPiPPA (GBG105)

GeparPiPPa-A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients with HER2+/HR+, PIK3CA mutant early breast cancer (BC);

Sibylle Loibl; 13. November 2022; 18:00-18:05; Presenter: Sabine Seiler (Abstract-Nr. 1027). Posterdownload

SASCIA (GBG 102)

Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT);

Frederick Marmé; 13. November 2022; 18:10-18:15; Presenter: Frederick Marmé. (Abstract-Nr. 504). Posterdownload

BMBC (GBG 79)

Impact of Tucatinib on Progression Free Survival in Patients with HER2 + Metastatic Breast Cancer and Brain Metastases;

Sibylle Loibl; 13. November 2022 18:30-18:35; Presenter: Sibylle Loibl (Abstract-Nr. 309). Posterdownload


35. Deutscher Krebskongress

News

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd